HLA match likelihoods for hematopoietic stem-cell grafts in the U.S. registry
- PMID: 25054717
- PMCID: PMC5965695
- DOI: 10.1056/NEJMsa1311707
HLA match likelihoods for hematopoietic stem-cell grafts in the U.S. registry
Abstract
Background: Hematopoietic stem-cell transplantation (HSCT) is a potentially lifesaving therapy for several blood cancers and other diseases. For patients without a suitable related HLA-matched donor, unrelated-donor registries of adult volunteers and banked umbilical cord-blood units, such as the Be the Match Registry operated by the National Marrow Donor Program (NMDP), provide potential sources of donors. Our goal in the present study was to measure the likelihood of finding a suitable donor in the U.S. registry.
Methods: Using human HLA data from the NMDP donor and cord-blood-unit registry, we built population-based genetic models for 21 U.S. racial and ethnic groups to predict the likelihood of identifying a suitable donor (either an adult donor or a cord-blood unit) for patients in each group. The models incorporated the degree of HLA matching, adult-donor availability (i.e., ability to donate), and cord-blood-unit cell dose.
Results: Our models indicated that most candidates for HSCT will have a suitable (HLA-matched or minimally mismatched) adult donor. However, many patients will not have an optimal adult donor--that is, a donor who is matched at high resolution at HLA-A, HLA-B, HLA-C, and HLA-DRB1. The likelihood of finding an optimal donor varies among racial and ethnic groups, with the highest probability among whites of European descent, at 75%, and the lowest probability among blacks of South or Central American descent, at 16%. Likelihoods for other groups are intermediate. Few patients will have an optimal cord-blood unit--that is, one matched at the antigen level at HLA-A and HLA-B and matched at high resolution at HLA-DRB1. However, cord-blood units mismatched at one or two HLA loci are available for almost all patients younger than 20 years of age and for more than 80% of patients 20 years of age or older, regardless of racial and ethnic background.
Conclusions: Most patients likely to benefit from HSCT will have a donor. Public investment in donor recruitment and cord-blood banks has expanded access to HSCT. (Funded by the Office of Naval Research, Department of the Navy, and the Health Resources and Services Administration, Department of Health and Human Services.).
Figures
Similar articles
-
Existence of HLA-Mismatched Unrelated Donors Closes the Gap in Donor Availability Regardless of Recipient Ancestry.Transplant Cell Ther. 2023 Nov;29(11):686.e1-686.e8. doi: 10.1016/j.jtct.2023.08.014. Epub 2023 Aug 14. Transplant Cell Ther. 2023. PMID: 37586457 Free PMC article.
-
Assessment of optimal size and composition of the U.S. National Registry of hematopoietic stem cell donors.Transplantation. 2004 Jul 15;78(1):89-95. doi: 10.1097/01.tp.0000132327.40702.97. Transplantation. 2004. PMID: 15257044
-
HLA-A, -B and -DR antigen frequencies of the London Cord Blood Bank units differ from those found in established bone marrow donor registries.Bone Marrow Transplant. 2000 Mar;25(5):475-81. doi: 10.1038/sj.bmt.1702197. Bone Marrow Transplant. 2000. PMID: 10713622
-
Alternative Donor Graft Sources for Adults with Hematologic Malignancies: A Donor for All Patients in 2017!Oncologist. 2017 Sep;22(9):1125-1134. doi: 10.1634/theoncologist.2017-0009. Epub 2017 May 25. Oncologist. 2017. PMID: 28546462 Free PMC article. Review.
-
How to select the best available related or unrelated donor of hematopoietic stem cells?Haematologica. 2016 Jun;101(6):680-7. doi: 10.3324/haematol.2015.141119. Epub 2016 May 31. Haematologica. 2016. PMID: 27252513 Free PMC article. Review.
Cited by
-
Allogeneic Hematopoietic Stem Cell Transplantation After Solid Organ Transplantation in Patients With Hematologic Malignancies Managed With Post-Transplant Cyclophosphamide-Based Graft-Versus-Host Disease Prophylaxis.J Hematol. 2024 Oct;13(5):250-258. doi: 10.14740/jh1327. Epub 2024 Oct 21. J Hematol. 2024. PMID: 39493605 Free PMC article.
-
Development of a quantitative prediction algorithm for human cord blood-derived CD34+ hematopoietic stem-progenitor cells using parametric and non-parametric machine learning models.Sci Rep. 2024 Oct 23;14(1):25085. doi: 10.1038/s41598-024-75731-4. Sci Rep. 2024. PMID: 39443591 Free PMC article.
-
Precision medicine results from equitable representation.Bone Marrow Transplant. 2024 Oct 21. doi: 10.1038/s41409-024-02430-z. Online ahead of print. Bone Marrow Transplant. 2024. PMID: 39433911
-
Access to Allogeneic Cell Transplantation Based on Donor Search Prognosis: An Interventional Trial.medRxiv [Preprint]. 2024 Sep 16:2024.09.16.24313494. doi: 10.1101/2024.09.16.24313494. medRxiv. 2024. PMID: 39371123 Free PMC article. Preprint.
-
Multiple measures for self-identification improve matching donors with patients in unrelated hematopoietic stem cell transplant.Commun Med (Lond). 2024 Oct 3;4(1):189. doi: 10.1038/s43856-024-00620-w. Commun Med (Lond). 2024. PMID: 39362987 Free PMC article.
References
-
- Copelan EA. Hematopoietic stem-cell transplantation. N Engl J Med. 2006;354:1813–26. - PubMed
-
- Kurtzberg J, Laughlin M, Graham ML, et al. Placental blood as a source of hematopoietic stem cells for transplantation into unrelated recipients. N Engl J Med. 1996;335:157–66. - PubMed
-
- Laughlin MJ, Eapen M, Rubinstein P, et al. Outcomes after transplantation of cord blood or bone marrow from unrelated donors in adults with leukemia. N Engl J Med. 2004;351:2265–75. - PubMed
-
- Eapen M, Rubinstein P, Zhang M-J, et al. Outcomes of transplantation of unrelated donor umbilical cord blood and bone marrow in children with acute leukaemia: a comparison study. Lancet. 2007;369:1947–54. - PubMed
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Research Materials